Renaissance Technologies LLC Purchases Shares of 715,838 Oncolytics Biotech Inc. $ONCY

Renaissance Technologies LLC acquired a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 715,838 shares of the company’s stock, valued at approximately $608,000. Renaissance Technologies LLC owned about 0.62% of Oncolytics Biotech as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the company. PFG Investments LLC grew its position in shares of Oncolytics Biotech by 131.0% in the first quarter. PFG Investments LLC now owns 52,900 shares of the company’s stock valued at $45,000 after purchasing an additional 30,000 shares during the last quarter. Virtu Financial LLC acquired a new stake in Oncolytics Biotech during the 4th quarter worth approximately $68,000. Connective Capital Management LLC acquired a new stake in Oncolytics Biotech during the 4th quarter worth approximately $131,000. XTX Topco Ltd acquired a new stake in Oncolytics Biotech during the 4th quarter worth approximately $69,000. Finally, Blair William & Co. IL bought a new stake in Oncolytics Biotech in the 4th quarter valued at $28,000. Institutional investors own 6.82% of the company’s stock.

Analyst Upgrades and Downgrades

ONCY has been the topic of several recent research reports. Wall Street Zen cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings raised shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Finally, HC Wainwright restated a “buy” rating on shares of Oncolytics Biotech in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Oncolytics Biotech Price Performance

Shares of NASDAQ:ONCY opened at $0.83 on Monday. The business’s 50 day simple moving average is $0.86 and its 200 day simple moving average is $0.92. Oncolytics Biotech Inc. has a 1 year low of $0.73 and a 1 year high of $1.51. The company has a market capitalization of $99.54 million, a P/E ratio of -2.45 and a beta of 1.13.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). On average, sell-side analysts anticipate that Oncolytics Biotech Inc. will post -0.25 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.